Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper session 2

Date

26 Feb 2019

Session

Proffered Paper session: New and early developments with new concepts

Presenters

Danique Giesen

Citation

Annals of Oncology (2019) 30 (suppl_1): i4-i9. 10.1093/annonc/mdz029

Authors

D. Giesen1, L.N. Broer1, M.N. Lub-De Hooge2, I. Popova3, B. Howng3, O. Vasiljeva3, E.G..E. de Vries1, M. Pool4

Author affiliations

  • 1 Medical Oncology, University Medical Center Groningen, 9713 GZ - Groningen/NL
  • 2 Clinical Pharmacy And Pharmacology, University Medical Center Groningen, 9713 GZ - Groningen/NL
  • 3 CytomX Therapeutics Inc., Suite 400 - South San Francisco/US
  • 4 Clinical Pharmacy And Toxicology, Leiden University Medical Center, 2333 ZA - Leiden/NL
More

Resources

Immune checkpoint inhibiting antibodies have antitumor activity across several tumor types, but can also elicit immune-mediated adverse events (imAEs). CX-072 is an investigational antibody prodrug (Probody™ therapeutic), reactive to the murine and human programmed death-ligand 1 (PD-L1) immune checkpoint. CX-072 can be activated to a fully avid antibody by tumor-associated proteases that remove the masking peptides blocking the antigen-binding domain, which may limit peripheral PD-L1 binding and therefore imAEs. CX-072 was radiolabeled with zirconium-89 (89Zr) to study its biodistribution and tumor- versus lymphoid tissue-targeting properties using positron emission tomography (PET).

Resources from the same session

Proffered Paper session 2

Presenter: Antoine Hollebecque

Session: Proffered Paper session: New and early developments with new concepts

Resources:

Abstract

Presentation

Webcast

Proffered Paper session 2

Presenter: Quan Sing Ng

Session: Proffered Paper session: New and early developments with new concepts

Resources:

Abstract

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings